Oxford Pharmascience - Interim results 2016

Tue, 13 Sep 2016, 12:15pm BST

Marcelo Bravo, Chief Executive Officer discusses their unaudited interim results for the six months to 30 June 2016. Highlights include the substantial progress being made  in commercialisation discussions regarding the Company's lead NSAID1 assets, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen.

Marcelo Bravo
Chief Executive Officer